Paper Alert: Mouse TREM2 Antibody Boosts Microglial Plaque Clean-Up
The monoclonal antibody activated TREM2 signaling on mouse microglia. It supported their survival and stimulated their clearance of amyloid plaques.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
Primary Care Physicians Unprepared to Handle Future Alzheimer’s Case Loads
A survey conducted by the Alzheimer’s Association finds that three-quarters of these physicians had little to no residency training in dementia care.
Dementia Research Institute to Double U.K. Coronavirus Testing
United Kingdom’s DRI pivots to fight COVID-19. The facility could test 10,000 samples per day.
A ‘Perfect Storm’ for Families Grappling with Dementia
From caregivers going it alone to understaffed nursing homes on lockdown, people with neurodegenerative disease and their caregivers are feeling enormous strain from the novel coronavirus. They are adapting to the new normal with technology.
A Phospho-Tau Plasma Assay for Alzheimer’s?
Two papers report that phosphorylated tau in the blood distinguishes people with AD from healthy controls and from people with frontotemporal and vascular dementias.
Low-Dose Aspirin Does Not Prevent AD, or Slow Cognitive Decline
A trial of nearly 20,000 participants found no benefit over five years.
New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better
At AAT-ADPD, researchers report how they built on prior reports that a person’s blood level of p-tau181 tells if they have Alzheimer’s.
AAT-AD/PD™ 2020 Conference: Advances in Alzheimer's and Parkinson's Therapies
New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better 217—The Best Phospho-Tau Marker for Alzheimer’s? In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned Confused About the DIAN-TU Trial Data? Experts Discuss Active Tau Vaccine:
Confused About the DIAN-TU Trial Data? Experts Discuss
The AAT-AD/PD conference hosted a virtual conversation about what the trial’s disappointing cognitive and tantalizing biomarker data might mean. Hidden between thank you’s and pledges to stay committed were substantive points of debate and context.
Active Tau Vaccine: Hints of Slowing Neurodegeneration
In a Phase 2 trial, the vaccine reportedly normalized the rise in plasma NfL, and appeared to lower CSF tau and retard brain atrophy.
‘Working from Home’: Do Gut Microbes Hold Sway Over Glia, Aβ?
Scientists report at AAT-AD/PD that they tightened a causal connection between gut microbes, microglial function, and protein deposits. In mice, that is.
Parkinson's Therapies Seek to Stem Progression
Trialists are shooting new arrows at the disease, including compounds that tweak autophagy, neuroinflammation, and glycolipid recycling.
With TREM2, Timing Is Everything
In a mouse model of amyloidosis, human wild-type TREM2 kept Aβ deposition at bay early on, but this defense became overwhelmed as plaques grew. The R47H AD risk variant never offered protection early on, and made things worse later.
α-Synuclein Antibody Misses Primary, May Have Signal on Secondaries
The first topline Phase 2 results from an antibody targeting Parkinson’s pathology, Roche’s prasinezumab, were a mixed bag. Next steps are unclear.
Which Cell Types Execute Your Genetic Risk? For AD and PD, Scientists Know.
For several neurodegenerative diseases, scientists identified which cell types exert a person’s inherited risk. In Alzheimer’s, it’s microglia; in Parkinson’s, it’s dopaminergic and enteric neurons—and oligodendrocytes.
Current Filters
No filters selected